Sunday, September 8

Browsing: Spherix Global Insights

Eli Lilly Poised to Nab First to Market Advantage with its IL-23 Inhibitor Mirikizumab in Ulcerative Colitis, Creating an Opportunity to Build a Loyal Base Ahead of AbbVie and Janssen's Respective IL-23 Entries, According to Spherix Global Insights

Health March 25, 2023

Gastroenterologists project mirikizumab will play a significant role in the treatment of ulcerative colitis EXTON, Pa., March 24, 2023 /PRNewswire/…

Ferring Pharmaceuticals' 1st in Class C.diff Treatment, Rebyota, Experiences a Positive Early Launch Ahead of Potential Competition, According to Spherix Global Insights

Health March 17, 2023

Aimmune/Seres’ SER-109 Poised to Challenge First to Market Ferring’s Rebyota for Treatment of Clostridioides Difficile EXTON, Pa., March 17, 2023…

Spherix Global Insights Continues Coverage of Biogen & Coherus Biosciences' Ranibizumab Biosimilars, Tracking Uptake and Perceptions of the First Commercially Available Biosimilars to Genentech's Lucentis

Health February 25, 2023

According to a survey of ophthalmologists, in the first six months of biosimilar availability, aided awareness and familiarity are marginal…

One Year Post-Launch of Argenx's Vyvgart for gMG, US Neurologists Confused on Best Approach to Treatment Dosing Schedules, According to Spherix Global Insights

Media February 25, 2023

Despite early satisfaction with Vyvgart, half of surveyed neurologists & neuromuscular specialists report uncertainty regarding re-dosing after the first treatment…

What's Hot

Levy Konigsberg Files Lawsuit on Behalf of 50 Men Who Were Sexually Abused as Juveniles at the New Jersey Training School

First Responders Action Group and The Independence Fund to Present All-Terrain Tracked Wheelchair to Former Las Vegas Law Enforcement Officer

SmartDry System Utilizes Secure AI Technology to Optimize Spray Drying

Browsing: Spherix Global Insights

Eli Lilly Poised to Nab First to Market Advantage with its IL-23 Inhibitor Mirikizumab in Ulcerative Colitis, Creating an Opportunity to Build a Loyal Base Ahead of AbbVie and Janssen's Respective IL-23 Entries, According to Spherix Global Insights

Ferring Pharmaceuticals' 1st in Class C.diff Treatment, Rebyota, Experiences a Positive Early Launch Ahead of Potential Competition, According to Spherix Global Insights

Spherix Global Insights Continues Coverage of Biogen & Coherus Biosciences' Ranibizumab Biosimilars, Tracking Uptake and Perceptions of the First Commercially Available Biosimilars to Genentech's Lucentis

One Year Post-Launch of Argenx's Vyvgart for gMG, US Neurologists Confused on Best Approach to Treatment Dosing Schedules, According to Spherix Global Insights

Levy Konigsberg Files Lawsuit on Behalf of 50 Men Who Were Sexually Abused as Juveniles at the New Jersey Training School

First Responders Action Group and The Independence Fund to Present All-Terrain Tracked Wheelchair to Former Las Vegas Law Enforcement Officer

SmartDry System Utilizes Secure AI Technology to Optimize Spray Drying

smartBreakfast Series 2024: llamada de atención para 2027

Levy Konigsberg Files Lawsuit on Behalf of 50 Men Who Were Sexually Abused as Juveniles at the New Jersey Training School

First Responders Action Group and The Independence Fund to Present All-Terrain Tracked Wheelchair to Former Las Vegas Law Enforcement Officer

SmartDry System Utilizes Secure AI Technology to Optimize Spray Drying

Must Watch

Levy Konigsberg Files Lawsuit on Behalf of 50 Men Who Were Sexually Abused as Juveniles at the New Jersey Training School

First Responders Action Group and The Independence Fund to Present All-Terrain Tracked Wheelchair to Former Las Vegas Law Enforcement Officer

SmartDry System Utilizes Secure AI Technology to Optimize Spray Drying

What's Hot

Browsing: Spherix Global Insights

Subscribe to Updates